National Heart & Lung Institute, Imperial College London, UK.
J Mol Cell Cardiol. 2013 Jun;59:67-75. doi: 10.1016/j.yjmcc.2013.02.001. Epub 2013 Feb 9.
Heart rates during ischaemia and reperfusion are possible determinants of reperfusion arrhythmias. We used ivabradine, a selective If current inhibitor, to assess the effects of heart rate reduction (HRR) during ischaemia-reperfusion on reperfusion ventricular arrhythmias and assessed potential anti-arrhythmic mechanisms by optical mapping. Five groups of rat hearts were subjected to regional ischaemia by left anterior descending artery occlusion for 8min followed by 10min of reperfusion: (1) Control n=10; (2) 1μM of ivabradine perfusion n=10; (3) 1μM of ivabradine+5Hz atrial pacing throughout ischaemia-reperfusion n=5; (4) 1μM of ivabradine+5Hz pacing only at reperfusion; (5) 100μM of ivabradine was used as a 1ml bolus upon reperfusion. For optical mapping, 10 hearts (ivabradine n=5; 5Hz pacing n=5) were subjected to global ischaemia whilst transmembrane voltage transients were recorded. Epicardial activation was mapped, and the rate of development of ischaemia-induced electrophysiological changes was assessed. HRR observed in the ivabradine group during both ischaemia (195±11bpm vs. control 272±14bpm, p<0.05) and at reperfusion (168±13bpm vs. 276±14bpm, p<0.05) was associated with reduced reperfusion ventricular fibrillation (VF) incidence (20% vs. 90%, p<0.05). Pacing throughout ischaemia-reperfusion abolished the protective effects of ivabradine (100% VF), whereas pacing at reperfusion only partially attenuated this effect (40% VF). Ivabradine, given as a bolus at reperfusion, did not significantly affect VF incidence (80% VF). Optical mapping experiments showed a delay to ischaemia-induced conduction slowing (time to 50% conduction slowing: 10.2±1.3min vs. 5.1±0.7min, p<0.05) and to loss of electrical excitability in ivabradine-perfused hearts (27.7±4.3min vs. 14.5±0.6min, p<0.05). Ivabradine administered throughout ischaemia and reperfusion reduced reperfusion VF incidence through HRR. Heart rate during ischaemia is a major determinant of reperfusion arrhythmias. Heart rate at reperfusion alone was not a determinant of reperfusion VF, as neither a bolus of ivabradine nor pacing immediately prior to reperfusion significantly altered reperfusion VF incidence. This anti-arrhythmic effect of heart rate reduction during ischaemia may reflect slower development of ischaemia-induced electrophysiological changes.
在缺血和再灌注期间的心率是再灌注心律失常的可能决定因素。我们使用伊伐布雷定,一种选择性 If 电流抑制剂,来评估缺血-再灌注期间心率降低(HRR)对再灌注室性心律失常的影响,并通过光学映射评估潜在的抗心律失常机制。五组大鼠心脏通过左前降支闭塞进行局部缺血 8 分钟,然后再灌注 10 分钟:(1)对照组 n=10;(2)伊伐布雷定 1μM 灌注 n=10;(3)伊伐布雷定+5Hz 心房起搏贯穿缺血-再灌注 n=5;(4)伊伐布雷定+5Hz 起搏仅在再灌注时;(5)再灌注时使用 100μM 的伊伐布雷定作为 1ml 推注。对于光学映射,10 个心脏(伊伐布雷定 n=5;5Hz 起搏 n=5)经历了全局缺血,同时记录跨膜电压瞬变。心外膜激活被映射,并评估缺血诱导的电生理变化的发展速度。伊伐布雷定组在缺血期间(195±11bpm 与对照组 272±14bpm,p<0.05)和再灌注期间(168±13bpm 与对照组 276±14bpm,p<0.05)观察到的 HRR 与再灌注室性颤动(VF)发生率降低(20%与 90%,p<0.05)有关。在缺血-再灌注期间起搏消除了伊伐布雷定的保护作用(100%VF),而仅在再灌注时起搏部分减弱了这种作用(40%VF)。在再灌注时给予伊伐布雷定作为推注剂并未显著影响 VF 发生率(80%VF)。光学映射实验表明,伊伐布雷定灌注可延迟缺血诱导的传导减慢(达到 50%传导减慢的时间:10.2±1.3min 与 5.1±0.7min,p<0.05)和电兴奋性丧失(27.7±4.3min 与 14.5±0.6min,p<0.05)。在缺血和再灌注期间给予伊伐布雷定可通过 HRR 降低再灌注 VF 发生率。缺血期间的心率是再灌注心律失常的主要决定因素。再灌注时的心率本身并不是再灌注 VF 的决定因素,因为伊伐布雷定的推注剂或再灌注前的起搏都不能显著改变再灌注 VF 的发生率。这种缺血期间心率降低的抗心律失常作用可能反映了缺血诱导的电生理变化发展较慢。